Sign Out
Safety in the treatment of infections during pregnancy has not been established. If administration to pregnant patients is considered necessary, its potential benefits should be weighed against the possible hazards to the foetus. There is evidence to suggest that when given systemically, fusidic acid can penetrate the placental barrier. The use of Foban in pregnancy requires that the potential benefits be weighed against the possible hazards to the foetus.
Safety in nursing mothers has not been established. When fusidic acid (as the sodium salt) has been given systemically, levels have been detected in breast milk, but with topical use the possible amount of drug present is unlikely to affect the infant.
